Atea Announces Update and Topline Results of MOONSONG Study

Evaluating AT-527 for COVID-19 in the Outpatient Setting

TOKYO, October 20, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on October 19 regarding update and topline results of MOONSONG study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting.

Please refer to the link below for details of the press release:

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2

###

Attachments

  • Original document
  • Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 20 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2021 23:40:05 UTC.